Our Bestsellers

Panmigrol Migraine Pain Relief 250 mg /250 mg /65 mg film coated tablets, Panmigrol Migraine and Headache Relief 250 mg /250 mg /65 mg film coated tablets (acetylsalicylic acid, paracetamol, caffeine).

Indications: Acute treatment of headache and of migraine attacks with or without aura. Dosage and administration: Adults (18 years and over) only. Headache: 1 tablet; if needed an additional tablet can be taken, with 4 to 6 hours between doses. Intense pain: 2 tablets. If needed an additional 2 tablets can be taken with 4 to 6 hours between doses. For episodic use, up to 4 days for headache. Migraine: Take 2 tablets when symptoms appear. If needed an additional 2 tablets can be taken, with 4 to 6 hours between doses. Intended for episodic use, up to 3 days for migraine. Maximum 6 tablets in 24 hours. Drink a full glass of water with each dose. Not recommended for use in children under 18 years. Exercise caution in the elderly, particularly those with low bodyweight. Contraindications: Hypersensitivity to the active ingredients or excipients. Patients in whom attacks of asthma, bronchospasm, angioedema, urticaria, or acute rhinitis are precipitated by acetylsalicylic acid or other NSAIDs. Active gastric or intestinal ulcer, gastrointestinal bleeding, or perforation and in patients with a history of peptic ulceration. Haemophilia or other haemorrhagic disorders. Severe cardiac failure severe hepatic failure, or severe renal impairment or failure. Third trimester of pregnancy. Precautions: Do not use with systemic NSAIDs, including cyclooxygenase-2 selective inhibitors, acetylsalicylic acid-containing or paracetamol-containing products or alcohol; if vomiting occurs with > 20% of migraines or bedrest is needed with >50% of migraine attacks; for more than 10 days per month for more than 3 months. Discontinue use immediately in suspected medication overuse headaches, gastrointestinal bleeds, or ulceration. GI bleeding risk may be enhanced by alcohol, corticosteroids and NSAIDs. GI bleeds / ulceration generally have more serious consequences in the elderly. Use special precaution in those with bronchial asthma, seasonal allergic rhinitis, nasal polyps, chronic obstructive pulmonary disease, or chronic infection of the respiratory tract. Use caution in undiagnosed migraineurs, or those with atypical symptoms, exclude other neurological conditions; patients with dehydration, gout, reduced uric acid excretion, congestive heart failure, impaired renal or hepatic function/disease, those with depleted glutathione levels (e.g. severely malnourished, anorexic, low body mass index, sepsis or chronic alcohol users) due to risk of hepatic dysfunction/failure, uncontrolled hypertension, severe glucose 6-phosphate dehydrogenase deficiency, diabetes mellitus, metrorrhagia, menorrhagia, alcohol dependence, hyperthyroidism, arrhythmia. May mask the signs and symptoms of infection, interfere with thyroid function tests, increase bleeding tendency during/after surgery, cause defects of haemostasis (monitoring is advised).Anticoagulants and medicines that inhibit platelet aggregation should not be used without a doctor’s supervision. Haematological and haemorrhagic effects can occur and may be severe, unusual bleeding symptoms should be reported to their physician. Acetylsalicylic acid can cause sodium and water retention which may exacerbate hypertension, congestive heart failure and renal impairment. Caution, regarding paracetamol, if used at therapeutic doses for a prolonged period or administered concomitantly with flucloxacillin due to increased risk of high anion gap metabolic acidosis (HAGMA), particularly in patients with severe renal impairment, sepsis, malnutrition and other sources of glutathione deficiency (e.g. chronic alcoholism). If suspected, discontinue use promptly and monitor closely, including measurement of urinary 5-oxoproline. Also use with caution if used with other potentially hepatotoxic medicinal products or products that induce liver microsomal enzymes. Should not be given to children and adolescents aged under 18 years unless specifically indicated because there is a possible association between acetylsalicylic acid and Reye’s syndrome. Rare cases of Kounis syndrome, with or without myocardial infarction, have been reported with acetylsalicylic acid. If confirmed, treatment should be discontinued immediately. Limit use of caffeine containing products. If no migraine relief from first 2-tablet dose, seek advice from physician. Contains 0.03mg benzoic acid per tablet. Side effects: Common: Nervousness, dizziness, nausea, abdominal discomfort. For full side effects please see summary of product characteristics. Legal category and RRP (excl. VAT): GSL: £3.13 P: £5.21 Product licence number: GSL: PL 44673/0229, P: PL 44673/0231 Product licence holder: Haleon UK Trading Limited, The Heights, Weybridge, Surrey, KT13 0NY, United Kingdom. Text prepared: September 2026

Panadol ActiFast Soluble Tablets (Paracetamol). Indications: For the treatment of most painful and febrile conditions, for example headache, including migraine and tension headaches, backache, toothache, rheumatic and muscle pains, dysmenorrhoea, sore throat and for relieving the fever, aches and pains of colds and flu. Dosage and administration: Adults, the elderly and children, 16 years and over: 1-2 tablets in at least half a tumbler of water up to four times daily as required. Children 10-15 years: One tablet dissolved in water up to four times daily as required. Children should not take for more than 3 days without doctor’s advice. Max 4 doses in any 24 hours and doses should not be repeated more frequently than every 4 hours. Children under 10 years: Not recommended. Contraindications: Hypersensitivity to any of the ingredients. Warnings and Precautions: Do not use with any other paracetamol-containing products. Those with renal or hepatic impairment should seek advice before use. Patients with persistent headaches or with non-serious arthritis who need to take painkillers every day should consult a doctor. Caution, regarding paracetamol, if used at therapeutic doses for a prolonged period or administered concomitantly with flucloxacillin due to increased risk of high anion gap metabolic acidosis (HAGMA), particularly in patients with severe renal impairment, sepsis, malnutrition and other sources of glutathione deficiency (e.g. chronic alcoholism). If suspected, discontinue use promptly and monitor closely, including measurement of urinary 5-oxoproline. Each tablet contains 427mg sodium, to be considered in patients on a sodium-controlled diet, and 62.5mg sorbitol. Patients with rare hereditary problems of fructose intolerance should not take this medicine. If symptoms persist, medical advice must be sought. Side effects: Very rare: Thrombocytopenia, agranulocytosis, anaphylaxis, cutaneous hypersensitivity reactions including skin rash, and angioedema. Very rare cases of serious skin reactions have been reported. Bronchospasm and hepatic dysfunction. Not known: High anion gap metabolic acidosis. Legal category and RRP (excl. VAT): 24s: £4.99 Product licence number: PL 44673/0083 Product licence holder: Haleon UK Trading Limited, The Heights, Weybridge, Surrey, KT13 0NY, United Kingdom. Text prepared: August 2026.